{"title":"探索1型糖尿病免疫治疗的进展和趋势：近二十年的综合文献计量分析。","authors":"Yixin Jiang, Zhou Xu, Yuting Wu, Xinglei Li, Jitao Ling, Yixuan Chen, Zicheng Zhu, Pingping Yang, Xiao Liu, Deju Zhang, Jianping Liu, Xiaoping Yin, Jing Zhang, Peng Yu","doi":"10.1111/obr.13888","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Immunotherapy is a crucial treatment for type 1 diabetes (T1D), yet analyses focusing on research priorities and trends in this field are limited. Therefore, this study employs bibliometric methods to systematically explore the current research status of immunotherapy for T1D.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Based on the Web of Science Core Collection Database, 1573 articles and review articles related to immunotherapy for T1D published from 2004 to 2023 were screened for bibliometric analysis. VOSviewer, CiteSpace, and R software were applied to comprehensively analyze the number of publications, journals, countries, authors, institutions, keywords, and references.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In the past two decades, the global annual publication rate has seen a significant increase of 238.24%. Almost 40% of all publications have appeared in the last 5 years, accounting for over 50% of total citations. Journals such as <i>Diabetes, Journal of Autoimmunity</i> and <i>Frontiers in Immunology</i> have exerted substantial influence. Collaboration across nations has been notably strong, with the United States leading the way. The University of Florida is the most productive institution. Terms like “nivolumab,” “ipilimumab,” “pembrolizumab,” and “immune checkpoint inhibitor(s)” gain considerable traction. The majority of research has clustered around themes such as immunomodulation, autoimmune diseases, immune checkpoint inhibitors, mesenchymal stem cells, and cell therapy. Precision medicine, immune checkpoint inhibitors, and nanotechnology are trending focal points in contemporary research.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The outcomes of the study are instrumental in enabling scholars to comprehend the evolving trajectory of immunotherapeutic approaches for T1D and facilitate the swift recognition of emerging research pathways.</p>\n </section>\n </div>","PeriodicalId":216,"journal":{"name":"Obesity Reviews","volume":"26 5","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring the progress and trends of immunotherapy for type 1 diabetes: A comprehensive bibliometric analysis spanning nearly two decades\",\"authors\":\"Yixin Jiang, Zhou Xu, Yuting Wu, Xinglei Li, Jitao Ling, Yixuan Chen, Zicheng Zhu, Pingping Yang, Xiao Liu, Deju Zhang, Jianping Liu, Xiaoping Yin, Jing Zhang, Peng Yu\",\"doi\":\"10.1111/obr.13888\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Immunotherapy is a crucial treatment for type 1 diabetes (T1D), yet analyses focusing on research priorities and trends in this field are limited. Therefore, this study employs bibliometric methods to systematically explore the current research status of immunotherapy for T1D.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Based on the Web of Science Core Collection Database, 1573 articles and review articles related to immunotherapy for T1D published from 2004 to 2023 were screened for bibliometric analysis. VOSviewer, CiteSpace, and R software were applied to comprehensively analyze the number of publications, journals, countries, authors, institutions, keywords, and references.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In the past two decades, the global annual publication rate has seen a significant increase of 238.24%. Almost 40% of all publications have appeared in the last 5 years, accounting for over 50% of total citations. Journals such as <i>Diabetes, Journal of Autoimmunity</i> and <i>Frontiers in Immunology</i> have exerted substantial influence. Collaboration across nations has been notably strong, with the United States leading the way. The University of Florida is the most productive institution. Terms like “nivolumab,” “ipilimumab,” “pembrolizumab,” and “immune checkpoint inhibitor(s)” gain considerable traction. The majority of research has clustered around themes such as immunomodulation, autoimmune diseases, immune checkpoint inhibitors, mesenchymal stem cells, and cell therapy. Precision medicine, immune checkpoint inhibitors, and nanotechnology are trending focal points in contemporary research.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The outcomes of the study are instrumental in enabling scholars to comprehend the evolving trajectory of immunotherapeutic approaches for T1D and facilitate the swift recognition of emerging research pathways.</p>\\n </section>\\n </div>\",\"PeriodicalId\":216,\"journal\":{\"name\":\"Obesity Reviews\",\"volume\":\"26 5\",\"pages\":\"\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2025-01-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/obr.13888\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/obr.13888","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
免疫治疗是1型糖尿病（T1D）的关键治疗方法，但对该领域的研究重点和趋势的分析有限。因此，本研究采用文献计量学方法，系统探讨T1D免疫治疗的研究现状。方法：基于Web of Science核心馆藏数据库，筛选2004 - 2023年发表的1573篇与T1D免疫治疗相关的文献及综述进行文献计量学分析。采用VOSviewer、CiteSpace、R软件对论文发表数量、期刊数量、国家数量、作者数量、机构数量、关键词数量、参考文献数量等进行综合分析。结果：近二十年来，全球年发表率显著提高了238.24%。近40%的出版物出现在最近5年，占总引用量的50%以上。《糖尿病》、《自身免疫杂志》和《免疫学前沿》等期刊已经产生了重大影响。在美国的领导下，各国之间的合作非常密切。佛罗里达大学是生产力最高的大学。像“nivolumab”、“ipilimumab”、“pembrolizumab”和“免疫检查点抑制剂”这样的术语获得了相当大的关注。大多数研究集中在免疫调节、自身免疫性疾病、免疫检查点抑制剂、间充质干细胞和细胞治疗等主题上。精准医学、免疫检查点抑制剂和纳米技术是当代研究的热点。结论：本研究结果有助于学者理解T1D免疫治疗方法的发展轨迹，并促进对新兴研究途径的快速识别。
Exploring the progress and trends of immunotherapy for type 1 diabetes: A comprehensive bibliometric analysis spanning nearly two decades
Introduction
Immunotherapy is a crucial treatment for type 1 diabetes (T1D), yet analyses focusing on research priorities and trends in this field are limited. Therefore, this study employs bibliometric methods to systematically explore the current research status of immunotherapy for T1D.
Methods
Based on the Web of Science Core Collection Database, 1573 articles and review articles related to immunotherapy for T1D published from 2004 to 2023 were screened for bibliometric analysis. VOSviewer, CiteSpace, and R software were applied to comprehensively analyze the number of publications, journals, countries, authors, institutions, keywords, and references.
Results
In the past two decades, the global annual publication rate has seen a significant increase of 238.24%. Almost 40% of all publications have appeared in the last 5 years, accounting for over 50% of total citations. Journals such as Diabetes, Journal of Autoimmunity and Frontiers in Immunology have exerted substantial influence. Collaboration across nations has been notably strong, with the United States leading the way. The University of Florida is the most productive institution. Terms like “nivolumab,” “ipilimumab,” “pembrolizumab,” and “immune checkpoint inhibitor(s)” gain considerable traction. The majority of research has clustered around themes such as immunomodulation, autoimmune diseases, immune checkpoint inhibitors, mesenchymal stem cells, and cell therapy. Precision medicine, immune checkpoint inhibitors, and nanotechnology are trending focal points in contemporary research.
Conclusion
The outcomes of the study are instrumental in enabling scholars to comprehend the evolving trajectory of immunotherapeutic approaches for T1D and facilitate the swift recognition of emerging research pathways.
期刊介绍：
Obesity Reviews is a monthly journal publishing reviews on all disciplines related to obesity and its comorbidities. This includes basic and behavioral sciences, clinical treatment and outcomes, epidemiology, prevention and public health. The journal should, therefore, appeal to all professionals with an interest in obesity and its comorbidities.
Review types may include systematic narrative reviews, quantitative meta-analyses and narrative reviews but all must offer new insights, critical or novel perspectives that will enhance the state of knowledge in the field.
The editorial policy is to publish high quality peer-reviewed manuscripts that provide needed new insight into all aspects of obesity and its related comorbidities while minimizing the period between submission and publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
